{
  "story_id": "67843c3ad40bf87a6a2266638f6870a2",
  "desk": "drm3",
  "revision": 2,
  "published_at": "2026-09-03T16:58:08.000Z",
  "content_hash": "89db768618279b2ef825c0705f42de91b64847475a34f2b772b6200312584342",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Daraxonrasib shows 42% response rate in pretreated RAS-mutant NSCLC in phase 1/2 trial",
    "dek": "Daraxonrasib achieved 42% response rate in pretreated RAS-mutant NSCLC patients in an MD Anderson-led trial.",
    "prose": "A phase 1/2 trial led by The University of Texas MD Anderson Cancer Center and published in the New England Journal of Medicine on 2026-09-02 evaluated the oral RAS inhibitor daraxonrasib in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC). [^1]\n\nIn a subgroup of docetaxel-naive patients who had previously received platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy, daraxonrasib showed a confirmed objective response rate of 42%, a median progression-free survival of 8.3 months, and a median overall survival of 16 months. [^2][^7] The oral RAS inhibitor daraxonrasib (brand name Rasonque) recently received FDA approval for metastatic pancreatic ductal adenocarcinoma. [^3] At the recommended phase 3 dose, 51% of patients experienced an adverse effect at grade 3 or higher, 71% had dose modifications, and 10% discontinued treatment; rash occurred in 90% of patients (8% grade 3 or higher) and gastrointestinal issues including diarrhea (73%), nausea (62%), and vomiting (54%) each occurred in less than 10% at grade 3 or higher. [^4][^6]\n\nDavid Hong, deputy chair of Investigational Cancer Therapeutics at MD Anderson and the study's lead, said the early results are encouraging because the few treatment options for these patients, such as docetaxel, often have modest benefit and substantial toxicities. [^5]",
    "cited": "[{\"statement\":\"A phase 1/2 trial led by The University of Texas MD Anderson Cancer Center and published in the New England Journal of Medicine on 2026-09-02 evaluated the oral RAS inhibitor daraxonrasib in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC).\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T21:00:05.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The trial reported that among 38 patients with NSCLC treated with 160-220 mg of daraxonrasib, the objective response rate was 42%, median duration of response was 11.5 months, median progression-free survival was 8.3 months, and median overall survival was 16 months.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T21:00:05.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The oral RAS inhibitor daraxonrasib (brand name Rasonque) recently received FDA approval for metastatic pancreatic ductal adenocarcinoma.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T16:58:08.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"]},{\"statement\":\"At the recommended phase 3 dose, 51% of patients experienced an adverse effect at grade 3 or higher, 71% had dose modifications, and 10% discontinued treatment; rash occurred in 90% of patients (8% grade 3 or higher) and gastrointestinal issues including diarrhea (73%), nausea (62%), and vomiting (54%) each occurred in less than 10% at grade 3 or higher.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T21:00:05.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"David Hong, deputy chair of Investigational Cancer Therapeutics at MD Anderson and the study's lead, said the early results are encouraging because the few treatment options for these patients, such as docetaxel, often have modest benefit and substantial toxicities.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T21:00:05.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"Grade 3 or higher adverse events occurred in 54% of patients in the trial, with pneumonia (10%), diarrhea (9%), rash (8%), and anemia (5%) occurring in at least 5% of patients.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T16:58:08.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"]},{\"statement\":\"In a subgroup of docetaxel-naive patients who had previously received platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy, daraxonrasib showed a confirmed objective response rate of 42%, a median progression-free survival of 8.3 months, and a median overall survival of 16 months.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T16:58:08.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "ffd9c84c73ac8e88cd98582f1bd2f9ec",
      "thread_id": "833f500d17491a790c4779e52d7d8d92",
      "thread_label": "RASolve 301 trial",
      "novelty": "UPDATE",
      "content_hash": "e2db79d69620a9d883614e3e4394eaf2e31e2548f683e7138087e5b9c04439b3",
      "last_published_at": "2026-09-03T16:58:08.000Z",
      "read_receipt": {
        "slice_hash": "82b8eb1bda6f6825e6a4b4603360fde611af49a7c156289c9c25e03be5a816f1",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDNUMTY6NDk6NDEuMDAwMDAwWiIsImlkIjoiYzU3MGE2NDljMTcxMDA2ZjgwMDhkOTRlMTY3YjFlZjAiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDNUMTc6MTk6MzYuMjMyMDAwWiIsImlkIjoiZjYxN2IyNzU4OGExNjY4YmFjOGEyZTBhZTEzYmUyMDYiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12166856,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "U351TfGYUfeMamVE-053wPGYBkBm9_fnzgUcVzESz6tTDThR-G0F4I8JoE9XfD7tySV_vzpUWD7FyRRxXFKWCg",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "compose": 3,
      "recomposed_at": "2026-09-05T20:30:46.349Z"
    },
    "written_at": "2026-09-04T06:33:28.185Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "A phase 1/2 trial led by The University of Texas MD Anderson Cancer Center and published in the New England Journal of Medicine on 2026-09-02 evaluated the oral RAS inhibitor daraxonrasib in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC).",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "The trial reported that among 38 patients with NSCLC treated with 160-220 mg of daraxonrasib, the objective response rate was 42%, median duration of response was 11.5 months, median progression-free survival was 8.3 months, and median overall survival was 16 months.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "The oral RAS inhibitor daraxonrasib (brand name Rasonque) recently received FDA approval for metastatic pancreatic ductal adenocarcinoma.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "At the recommended phase 3 dose, 51% of patients experienced an adverse effect at grade 3 or higher, 71% had dose modifications, and 10% discontinued treatment; rash occurred in 90% of patients (8% grade 3 or higher) and gastrointestinal issues including diarrhea (73%), nausea (62%), and vomiting (54%) each occurred in less than 10% at grade 3 or higher.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "David Hong, deputy chair of Investigational Cancer Therapeutics at MD Anderson and the study's lead, said the early results are encouraging because the few treatment options for these patients, such as docetaxel, often have modest benefit and substantial toxicities.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "Grade 3 or higher adverse events occurred in 54% of patients in the trial, with pneumonia (10%), diarrhea (9%), rash (8%), and anemia (5%) occurring in at least 5% of patients.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "In a subgroup of docetaxel-naive patients who had previously received platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy, daraxonrasib showed a confirmed objective response rate of 42%, a median progression-free survival of 8.3 months, and a median overall survival of 16 months.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}